|
|
|
| Correlation of HPV Infection with Immunoregulatory Imbalance and Abnormal Cell Proliferation in Patients with Cervical Lesions |
| HOU Ying, LI Yanmei, LI Xiulan, et al |
| Beijing You'an Hospital, Capital Medical University, Beijing 100069, China |
|
|
|
|
Abstract Objective: To investigate the relationship between human papillomavirus (HPV) infection and immune dysregulation and abnormal cell proliferation in cervical lesions. Methods: In order to investigate this relationship, a study was conducted from January 2020 to April 2022, in which 56 cases of high-risk HPV-infected cervical lesion patients (high-risk HPV group), 51 cases of low-risk HPV-infected cervical lesion patients (low-risk HPV group), 57 cases of HPV-negative cervical lesion patients (HPV-negative group), and 60 healthy women (normal group) were selected. The cellular and humoral immune indicators, cytokines, p16 protein, Ki67 protein, Prdx4 mRNA, and STAT3 mRNA were compared among the groups. Results: The CD4+ cells, immunoglobulin G (IgG), and immunoglobulin A (IgA) levels were significantly lower in the high-risk HPV group and low-risk HPV group than in the HPV-negative group and normal group (P<0.05). Furthermore, the levels of CD4+ cells, IgG and IgA were significantly lower in the high-risk HPV group than in the low-risk HPV group (P<0.05). The levels of interleukin-2 (IL-2) were significantly lower in the high-risk HPV group and low-risk HPV group than in the HPV-negative group and normal group (P<0.05), with the high-risk HPV group showing significantly lower IL-2 levels than the low-risk HPV group (P<0.05). The levels of interleukin-4 (IL-4), interleukin-17 (IL-17), and transforming growth factor-β (TGF-β) were significantly higher in the high-risk HPV group and low-risk HPV group than in the HPV-negative group and normal group (P<0.05), with the high-risk HPV group showing significantly higher levels of IL-4, IL-17, and TGF-β than the low-risk HPV group (P<0.05).The positive expression rates of p16 and Ki67 proteins were significantly higher in the high-risk HPV group and low-risk HPV group than in the HPV-negative group and normal group (P<0.05). The relative expression levels of Prdx4 and STAT3 mRNA were significantly higher in the high-risk HPV group and low-risk HPV group than in the HPV-negative group and normal group (P<0.05), with the high-risk HPV group showing significantly higher levels of Prdx4 and STAT3 mRNA than the low-risk HPV group (P<0.05). Conclusion: HPV infection exacerbates immune dysregulation and promotes abnormal cell proliferation in cervical lesion patients, particularly in high-risk HPV infections.
|
|
|
|
|
|
[1] Szymonowicz KA,Chen J.Biological and clinical aspects of HPV-related cancers[J].Cancer Biol Med,2020,17(4):864-878.
[2] Zheng JJ,Miao JR,Wu Q,et al.Correlation between HPV-negative cervical lesions and cervical microenvironment[J].Taiwan Obstet Gynecol,2020,59(6):855-861.
[3] 许艳茹,林景涛,周正维,等.CT、NG与HPV感染的关系及与宫颈病变发生的相关性[J].分子诊断与治疗杂志,2022,14(12):2215-2218.
[4] McBride AA.Human papillomaviruses:diversity,infection and host interactions[J].Nat Rev Microbiol,2022,20(2):95-108
[5] Jee B,Yadav R,Pankaj S,et al.Immunology of HPV-mediated cervical cancer:current understanding[J].Int Rev Immunol,2021,40 (5):359-378
[6] 樊慧清.P16、Ki67在不同级别宫颈上皮内病变的表达及宫颈锥切术后HPV持续感染的影响因素[D].河北医科大学,2021.
[7] Piyathilake CJ,Badiga S,Burkholder GA,et al.The accuracy of HPV genotyping in isolation and in combination with CD4 and HIV viral load for the identification of HIV-infected women at risk for developing cervical cancer[J].Cancer Med,2021,10(5):1900-1909.
[8] 张永会,胡红娟,彭强丽,等.健脾解毒方治疗对HR-HPV持续性感染患者外周血 CD4+、CD8+及HR-HPV DNA表达水平的影响[J].中华医院感染学志,2021,31(10):1470-1475.
[9] 窦艳艳,杨凤杰.人乳头瘤病毒感染阳性的宫颈癌患者血清T细胞亚群水平变化[J].中国卫生工程学,2022,21(3):483-485.
[10] Meng JW,Song JH.Association between interleukin-2,interleukin-10,secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions[J].Oncol Lett,2019,18(5):5543-5548.
[11] 杨广丽.阴道灌洗液中IL-6、IL-17、IFN-γ、TGF-β检测在宫颈高危型HPV感染患者中的临床意义[J].中国现代医药杂志,2020,22(7):23-26. |
|
|
|
2023, Vol. 29 
